{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-25-042304","form_type":"8-K","ticker":"FEMY","cik":"0001339005","company_name":"FEMASYS INC","filed_at":"2025-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.188548+00:00","generated_at":"2026-05-16T19:46:49.641969+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Femasys Q3 sales up 31% to $729K; FDA clears FemBloc final pivotal trial; $12M financing extends runway","bullets":["Net loss $4.19M ($0.10/sh) vs $5.41M ($0.24/sh) a year ago on lower R&D spend.","Sales rose 31.4% YoY to $729,394, driven by FemBloc product sales.","FDA IDE approval to commence final phase of FemBloc pivotal trial for U.S. approval.","Closed $12M secured convertible note offering with warrants for up to $58M total potential funding.","Cash $4.6M at Q3 end; with recent financing, runway extended into September 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-25-042304","json":"https://secwatch.observer/filing/0001140361-25-042304.json","markdown":"https://secwatch.observer/filing/0001140361-25-042304.md","text":"https://secwatch.observer/filing/0001140361-25-042304.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1339005/000114036125042304/0001140361-25-042304-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1339005/000114036125042304/ef20059086_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T19:46:49.641969+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}